Biochemical Characterization Of Mapmodulin, a Protein That Binds Microtubule-associated Proteins*

Nirit Ulitzur, Carmen Rancano, and Suzanne R. Pfeffer‡

From the Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305-5307

© 1997 by The American Society for Biochemistry and Molecular Biology, Inc.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 272, No. 48, Issue of November 28, pp. 30577–30582, 1997

Mapmodulin is a 31-kDa protein that stimulates the microtubule- and dynein-dependent localization of Golgi complexes in semi-intact Chinese hamster ovary cells. We have shown previously that it binds the microtubule binding domains of the microtubule-associated proteins, MAP2, MAP4, and tau. We also showed that mapmodulin is identical to a protein named PHAPI (Vaesen, M., Barnikol-Watanabe, S., Götz, H., Awni, L.A., Cole, T., Zimmermann, B., Kratzin, H.D. and Hilschmann, N. (1994) Biol. Chem. Hoppe-Seyler 375, 113–126). We report here that mapmodulin is a phosphoprotein that is predominantly cytosolic but is also found peripherally associated with endoplasmic reticulum and Golgi membranes in mammalian cells. The protein occurs as a trimer in cytosol, and phosphorylation is required for its microtubule-associated protein-binding activity. Heat treatment of nonphosphorylated mapmodulin can render it competent for binding to microtubule-associated proteins, suggesting that phosphorylation induces a conformational change in mapmodulin. Finally, despite identity in polyepitope sequence with a protein reported to act as an inhibitor of protein phosphatase 2A, native mapmodulin was not able to inhibit protein phosphatase 2A in Chinese hamster ovary cell cytosol.

When isolated Golgi complexes are mixed with broken CHO1 cells, they enter the cytoplasm and accumulate at the centrosome. This “Golgi capture” process requires intact microtubules, cytoplasmic dynein, ATP hydrolysis, as well as cytosolic and membrane-associated proteins (1). We have recently described the purification of a 31-kDa protein, named mapmodulin, that appears to be essential for Golgi capture (2).

We have shown that mapmodulin binds MAP4, MAP2, and tau (2). It binds free MAPs in strong preference to microtubule-bound MAPs and does so via the microtubule-binding domain of the MAP. Binding to each of these MAPs requires the carboxy-terminal portion of mapmodulin and decreases the rate with which MAPs can subsequently re-bind to microtubules. We have proposed that mapmodulin represents a novel class of proteins that functions to displace MAPs transiently from microtubules, thereby permitting organelle translocation (2).

Peptide sequence analysis of mapmodulin revealed complete identity with “putative HLA-associated protein-I” (PHAPI; Ref. 3). PHAPI was purified from lymphoblastoid cell cytosol based on its ability to bind to a peptide corresponding to the cytoplasmic domain of the human HLA class II DR2a-chain. Despite the basic nature of the α-chain peptide employed, control experiments showed that basic residues were not sufficient for PHAPI binding (3). Preliminary immunoelectron microscopy detected the protein over all cellular compartments, including the cytoplasm, membranes, and nucleus (3). The same protein was also purified independently as LANP (4), pp32 (5), and I1 (6, 7). I1 was reported to specifically inhibit protein phosphatase 2A in in vitro assays (6, 7).

In this paper, we further characterize mapmodulin/PHAPI and show that it is an abundant cytosolic phosphoprotein, partially associated with ER and Golgi membranes. The predominant form of mapmodulin in cells is phosphorylated; phospho-mapmodulin binds to the MAP4 microtubule-binding domain with higher affinity than the dephosphorylated form, suggesting that this posttranslational modification plays a role in regulating MAP binding.

Sequence alignments revealed that mapmodulin shares limited structural homology with CLIP-170, a putative endosome-microtubule linker protein (8, 9). Despite this sequence similarity, mapmodulin does not serve as a linker between the Golgi complex and microtubules. Finally, neither native CHO mapmodulin nor bacterially expressed, His-tagged mapmodulin inhibit protein phosphatase 2A under physiological conditions, in contrast to reports from another laboratory for the protein purified as I1 (6, 7).

EXPERIMENTAL PROCEDURES

Materials—Antibodies, CHO mapmodulin, recombinant, His-tagged mapmodulin, and Golgi membranes were prepared as described previously (2).

In Vitro Golgi Binding Assay—Purified bovine tubulin (10 mg/ml) was polymerized by incubation with 1 mM GTP and 20 μM taxol for 15 min at 37 °C. After ultracentrifugation, pellets were resuspended in PE buffer (85 mM K-PIPES, pH 7.0, 1 mM EGTA, 1.5 mM MgSO4,10 μM taxol) to a final concentration of 1 mg/ml. In a standard reaction, 6 μg of KCl-stripped Golgi membranes were incubated with 20 μg of microtubules in PE buffer for 30 min at 37 °C in the presence or absence of 100 μg of cytosol. The reaction mix (50 μl) was layered over 40% sucrose in PE buffer and spun at 35000 rpm for 30 min at 25 °C in a TLA-100 rotor (Beckman Instruments, Palo Alto, California). Pellets were subjected to an N-acetylglucosamine transferase 1 enzymatic assay (2).

Cell Fractionation and Immunoblot Analysis—CHO cells were homogenized in SEAT buffer (250 mM sucrose, 10 mM triethanolamine, 10 mM acetic acid, 1 mM EDTA, pH 7.4) by 5 passages through a 22-gauge needle. Nuclei and debris were pelleted by centrifugation at 100 000 g for 5 min in an Eppendorf centrifuge. The postnuclear supernatant was centrifuged at 60 000 rpm for 30 min at 4 °C in a Beckman TLA-100 rotor, and aliquots of the pellet and supernatant fractions were analyzed by SDS-PAGE followed by immunoblotting.

Immunofluorescence—Immunofluorescence was carried out essentially as described by Warren et al. (10). The cells were permeabilized using 0.5% saponin or 0.2% Triton X-100 in PBS for 5 min and then
Mapmodulin, a MAP-binding Phosphoprotein

RESULTS

Mapmodulin was purified from CHO cytosol on the basis of its ability to stimulate the dynein- and microtubule-dependent localization of Golgi complexes in broken cells (2). As described above, mapmodulin is identical to PHAPI, a protein that was purified from human lymphoblastoid B-cell line cytosol on the basis of its capacity to bind peptides representing the basic, cytosolic tail of HLA class II a-chain (3).

Mapmodulin (PHAPI) has a predicted mass of 28.4 kDa (3). When the native protein purified from CHO cytosol is resolved by SDS-PAGE under denaturing conditions, the protein has an apparent molecular mass of 31 kDa (Fig. 1, lane 2); a His-tagged, carboxyl-terminal truncated form, which lacks the acidic region encoded by residues 164–249, was also generated (2) (lane 3).

Mapmodulin chromatographs as an apparent oligomer upon gel filtration chromatography. When purified CHO cell mapmodulin was fractionated on a Superdex 200 FPLC column at physiological ionic strength (PBS), it eluted just ahead of the 76-kDa marker, suggesting that under physiological conditions, the native protein may in fact be a trimer (Fig. 2A). Cross-linking experiments carried out with purified, CHO cell mapmodulin (Fig. 2B) or recombinant, His-tagged mapmodulin (Fig. 2C) revealed that both forms of the protein form trimers. These data suggest that mapmodulin is likely a trimer in CHO cytosol. In addition, the ability of the carboxyl-terminal truncated form to form apparent trimers indicates that the carboxyl terminus of the protein is not required for mapmodulin homo-oligomerization.

Mapmodulin Localization—Polyclonal antibodies were raised against purified, CHO mapmodulin and recombinant, His-tagged mapmodulin. In total CHO cytosol, anti-native mapmodulin recognized a single polypeptide by immunoblot analysis with an apparent mass of 31 kDa (Fig. 1, lane 4). The CHO cell protein was smaller in mass than the purified, recombinant mapmodulin, which contained additional histidine residues (Fig. 1, lane 5). The polyclonal anti-CHO mapmodulin antibodies were used to localize mapmodulin by indirect immunofluorescence of CHO cells. Using mild conditions for permeabilization (0.5% saponin), interphase cells exhibited an
Overall diffuse staining, as would be expected from a cytosolic protein. More rigorous detergent pre-extraction (0.2% Triton X-100) led to a clearer image of uniform labeling of what appeared to be both ER and Golgi membranes, suggesting that mapmodulin occurs in both soluble and membrane-bound forms (Fig. 3A). With longer times of detergent extraction, nuclear staining is also observed. These findings were consistent with previous preliminary immunoelectron microscopic localization of PHAPI in lymphoblastoid cells (3).

To verify the membrane interaction of mapmodulin, we subjected a CHO cell postnuclear supernatant to flotation in a sucrose gradient. In these gradients, membrane-bound organelles float upward and can be readily resolved from cytosolic proteins. As shown in Fig. 3B, the bulk of a Golgi marker, N-acetylglucosamine transferase I (○, fractions 3–9), was well separated from the bulk of the protein that remained at the bottom of the gradient (○, fractions 15–22). Endosomes and lysosomes co-fractionate with Golgi on such gradients; ER membranes float to an intermediate density (not shown). While the majority of mapmodulin fractionated with soluble protein (●), a significant amount was detected in the lighter density, membrane-enriched regions of the gradient. These biochemical data confirm that mapmodulin occurs in both soluble and membrane-associated forms. Quantitation of fractionated CHO cells revealed that 3–5% of the cellular pool of mapmodulin is membrane-bound. This fraction can be stripped off of membranes with 0.5 M KCl (data not shown).

Mapmodulin Shows Discrete Homology to CLIP-170—Fig. 4A presents the sequence of PHAPI (3) and the tryptic peptides we obtained from purified, CHO mapmodulin. The mapmodulin/PHAPI sequence is comprised of a generally basic, Leu/Ile-rich, amino-terminal region and a long, acidic carboxyl-terminal portion; the protein has an overall calculated pI of 3.7. The sequence does not contain consensus nucleotide binding sites and thus is unlikely to represent a molecular motor. Interestingly, we found that mapmodulin shares small segments of similarity with CLIP-170, the putative cytoplasmic linker between endosomes and microtubules (8, 9). Three of the four segments display 35–60% sequence identity and 53–80% similarity without introduction of any gaps or deletions (Fig. 4B). The homologous segments reside within the amino-terminal region of mapmodulin and the carboxyl-terminal domain of CLIP-170, and their order and relative orientation is conserved between the two proteins. The highest level of identity (60%) was found between residues 145–154 of mapmodulin and residues 1313–1322 of CLIP-170, part of the putative organelle-binding domain of CLIP-170 (9). While this homology is intriguing, its true significance is at present, entirely unclear.

Mapmodulin Does Not Mediate Binding of Golgi to Microtubules—Given the sequence similarity with CLIP-170, it was of interest to determine whether mapmodulin can link the Golgi to microtubules. For this purpose, we used an assay established by Kreis and co-workers (8, 11) to detect CLIP-170-mediated, endosome-microtubule interactions. Taxol-stabilized bovine microtubules were incubated with KCl-treated Golgi membranes in the presence or absence of added CHO cytosol at 37 °C for 30 min. Reactions were then centrifuged through a sucrose cushion to separate free Golgi membranes from those that may have become microtubule-bound. The extent of Golgi binding was then quantified by measuring the level of Golgi-specific enzyme, N-acetylglucosamine transferase I, in the microtubule pellet.

As shown in Table I, cytosol increased the association of KCl-treated Golgi with microtubules at least 7-fold. In contrast, CHO cell mapmodulin alone did not stimulate the association of KCl-treated Golgi with microtubules by more than a few percent. We estimate CHO cytosol to contain ~50 ng of mapmodulin/100 µg, comparable with the amount tested in these experiments (64 ng). Thus, mapmodulin does not mediate the binding of Golgi complexes to microtubules under these experimental conditions, when added at concentrations similar to those found in cytosol. This feature distinguishes mapmodulin functionally from CLIP-170, which has been shown to mediate endosome-microtubule association under very similar conditions (8, 11).

Mapmodulin Is a Phosphoprotein—Two-dimensional gel analyses of mapmodulin in CHO cytosol revealed that the protein is phosphorylated. As shown in Fig. 5A, antibodies raised against native CHO mapmodulin recognized one major and one minor spot on a two-dimensional gel immunoblot. When cytosol was treated with alkaline phosphatase, the bulk of the immunoreactivity shifted to the position of the slightly smaller, less acidic spot (panel B). Thus, the major form of mapmodulin is phosphorylated in CHO cytosol.

Antibodies raised against the recombinant protein were much less effective in recognizing the phosphorylated form of mapmodulin. Only after phosphatase treatment of CHO cytosol did the antibody yield a significant reaction product (Fig. 5, C and D). It is very likely that the E. coli cells used for expression purposes lack the kinases responsible for mapmodulin phos-
Phosphorylation. These experiments show that mapmodulin appears primarily as a phosphoprotein in CHO cytosol. It should be noted that a smaller (28 kDa; pI 5.44) immunoreactive spot was occasionally detected in some cytosol preparations. This form was only recognized by anti-recombinant mapmodulin antibodies. Since distinct splice variants of PHAPI have appeared in the database, this spot may represent the product of a distinctly spliced mRNA.

Phosphorylation Is Needed for Mapmodulin-MAP4 Interaction—Since our previous MAP binding experiments were carried out with native, phosphorylated CHO mapmodulin (2), we were interested in determining the potential importance of mapmodulin phosphorylation in terms of MAP binding. For this purpose, we used a solid phase immunoassay to compare the binding of phospho- and dephospho-mapmodulin to the microtubule binding, carboxyl-terminal domain of MAP4 (12). As shown in Fig. 6, nonphosphorylated, recombinant mapmodulin displayed only barely detectable binding to the carboxyl-terminal domain of MAP4, relative to that observed with phosphorylated mapmodulin in CHO cytosol. CHO cytosol, treated with (B and C) or without (A and D) alkaline phosphatase (p'tase), was analyzed by two-dimensional gel electrophoresis. Gels were transferred to nitrocellulose, and blots were reacted with either anti-native mapmodulin (A and B) or anti-recombinant mapmodulin (C and D) polyclonal sera as indicated at right.
Mapmodulin, a MAP-binding Phosphoprotein

FIG. 6. Phosphorylation is required for binding of mapmodulin to the carboxyl terminus of MAP4. Microtiter wells were coated with MAP4-carboxyl-terminal domain GST-fusion protein. After blocking the wells, either CHO-purified mapmodulin, recombinant mapmodulin, or boiled recombinant mapmodulin was added (each at 0.25 μM). Bound protein was detected using polyclonal anti-mapmodulin antibodies.

FIG. 7. Native mapmodulin does not inhibit protein phosphatase 2A. The activity of cytosolic phosphatases was measured with 32P-phosphorylase a as substrate.

recombinant mapmodulin/PHAPI chromatograph as ~90-kDa species (Fig. 2). This molecular distinction may in part explain the discrepancy between our results and those of Li et al. (7).

DISCUSSION

Mapmodulin stimulates the microtubule and cytoplasmic dynein-dependent localization of Golgi complexes to the centrosomes of semi-intact Chinese hamster ovary cells (2). In our efforts to understand how this protein stimulates Golgi localization, we found that mapmodulin binds the microtubule-associated proteins, MAP2, MAP4, and tau, via their homologous microtubule-binding domains (2). We proposed that this property may allow mapmodulin to displace MAPs from the path of organelles translocating along microtubules toward the centrosome.

In this paper, we have characterized the cellular localization and posttranslational modification of this novel, MAP-binding protein. By fractionation, the protein is predominantly cytosolic, but at least ~5% can be shown to float in a sucrose gradient with endosome and Golgi-associated marker proteins. This was consistent with membrane localization determined by immunofluorescence light microscopy. Gel filtration experiments suggested that the cytosolic protein occurs as a trimer. In addition, two-dimensional gel analysis, carried out in conjunction with alkaline phosphatase treatment, confirmed that the major form of mapmodulin in CHO cytosol is phosphorylated.

The primary structure of mapmodulin has two striking features. The carboxyl terminus is highly enriched in acidic residues, and the presence of this domain is required for MAP binding (2). The amino-terminal portion contains a high proportion of leucine residues and a sequence that matches the consensus for a leucine-rich repeat. Leucine-rich repeats are relatively short motifs found in proteins of diverse function and localization. They appear to be able to form amphipathic structures with hydrophobic surfaces capable of interacting with other proteins. Since mapmodulin and carboxyl-terminal truncated mapmodulin apparently form trimers, it seems reasonable to propose that homo-oligomerization is mediated by the leucine-rich repeats.

Here we have shown that mapmodulin phosphorylation is required for MAP binding. Although the kinases responsible for mapmodulin phosphorylation remain to be identified, multiple casein kinase II recognition motifs are present in the amino-terminal domain of the protein. Perhaps the amino-terminal portion interacts strongly with the carboxyl-terminal, MAP-binding domain in the nonphosphorylated state. Phosphorylation might lessen this interaction to permit mapmodulin-MAP interaction. Our finding that boiling of nonphosphorylated mapmodulin did not inhibit protein phosphatase 2A activity in CHO cytosol. This result was obtained and recombinant mapmodulin failed to have any influence on phosphatase activity in this assay. This result was obtained and recombinant mapmodulin was added (each at 0.25 μM). Bound protein was detected using polyclonal anti-mapmodulin antibodies.

During the course of our study, Li et al. (6, 7) reported the purification of a ~250 kDa potent and specific inhibitor of protein phosphatase 2A, which they named I1PP2A. Sequence analysis of this inhibitor revealed identity with PHAPI. This finding made it incumbent upon us to check whether native mapmodulin possesses phosphatase 2A-inhibitory activity.

Phosphorylase a was used as a substrate, and CHO cytosol was used as the source of protein phosphatases 1 and 2A. Fig. 7 shows that commercial I1PP2A was a strong inhibitor of phosphatase 2A activity in CHO cytosol. In contrast, both native and recombinant mapmodulin failed to have any influence on phosphatase activity in this assay. This result was obtained with numerous cytosol and mapmodulin preparations. In summary, native mapmodulin, as purified by our published procedure, does not display phosphatase 2A inhibitory activity using phosphorylase a as substrate. It is important to note that unlike I1PP2A, which has an apparent $M_w$ of ~250,000, native and recombinant mapmodulin/PHAPI chromatograph as ~90-kDa species (Fig. 2). This molecular distinction may in part explain the discrepancy between our results and those of Li et al. (7).
Mapmodulin generates a protein that is competent for MAP binding is consistent with this hypothesis.

Recombinant mapmodulin was active in our in vitro Golgi localization assay only when reactions were supplemented with additional cytosol (2). It is likely that recombinant mapmodulin is rapidly phosphorylated by the residual cytosol present in our broken cells, converting it to an active conformation.

Sequence analysis of mapmodulin revealed four consecutive stretches of homology between the carboxyl-terminal region of CLIP-170 and the amino-terminal region of mapmodulin. Pierre et al. (9) found that the carboxyl-terminal domain appears to be involved in anchoring the protein to patches at the plasma membrane, while the conserved repeated motif present in the amino-terminal domain of CLIP-170 regulates its binding to microtubules in vivo. Future experiments will be needed to determine whether the CLIP-170-related portions of mapmodulin mediate membrane association.

Despite sequence similarity with CLIP-170, mapmodulin does not appear to represent the key cytosolic factor responsible for direct Golgi binding to microtubules. Mapmodulin failed to enhance significantly the association of KCl-treated Golgi membranes with microtubules using a microtubule co-sedimentation assay. Under identical conditions, total CHO cytosol strongly stimulated microtubule co-sedimentation. A similar assay enabled Kreis and co-workers (8) to show that CLIP-170 linked endocytic carrier vesicles to microtubules.

What is the significance of the identity of mapmodulin with PHAPI? At low ionic strength (10 mM PIPES, pH 6.6, 40 mM NaCl), PHAPI bound to the peptide KLGKLRKSAERRRGL but not to the peptide KAARKAAARRA; PHAPI was released by increasing the NaCl concentration above 160 mM. Because of the charge similarity between the HLA-DR2 peptide and the corresponding control peptide, the authors concluded that the interaction showed sequence specificity beyond the general charge distribution of the lysine and arginine residues (3). Although we cannot explain the physiological significance of PHAPI (mapmodulin) binding to the HLA-DR2a peptide, it is interesting to note that MAP proteins utilize a basic domain for interaction with microtubules (reviewed in Ref. 13). An example of this tubulin-binding sequence, which is repeated in MAP2 protein, KCGSLKNIRHRPGGG, shares remarkable compositional similarity with the test sequence employed to isolate PHAPI. The overall spacing of basic residues and the presence and relative distribution of the specific, bulky amino acids leucine, asparagine, and proline are strikingly conserved between the HLA-DR2a peptide and the tubulin binding domain of MAP2.

Mapmodulin/PHAPI is likely the human homolog of a protein described as rat “leucine-rich acidic nuclear protein” (LANP; 83.6% amino acid identity; Refs. 4 and 14). LANP was reported to be localized to the nuclei and cytoplasm of Purkinje cells. Our immunofluorescence analysis using affinity-purified antibodies and a variety of cell types did not reveal significant quantities of mapmodulin in the nucleus; mapmodulin was predominantly in the cytosol and on Golgi and ER membranes. It remains possible that our antibody recognizes a different phosphorylated form of mapmodulin than that studied in this report.

Chen et al. (5) have recently reported the cloning of cDNAs encoding the human and murine PHAPI, which they named pp32. This protein was previously identified as a phosphoprotein that is highly expressed in cancer tissues and self-renewing cell populations. Our data confirm the conclusion that PHAPI is a phosphoprotein in CHO cells.

Li et al. (6, 7) purified and cloned a potent and specific protein phosphatase 2A inhibitor, I$_1^{PP2A}$, which they later found to be identical to PHAPI. In the present study, we confirmed that commercial I$_1^{PP2A}$ is a potent phosphatase inhibitor. However, we were unable to detect any phosphatase inhibitory activity in preparations of either native or recombinant mapmodulin. It is important to note that the purification procedure of both bovine kidney and E. coli-purified I$_1^{PP2A}$ includes poly(1-lysine)-agarose and elution with high salt (6, 7). Moreover, I$_1^{PP2A}$ was reported to elute from a gel filtration column as a $\geq$ 250 kDa form, rather than the native $\sim$90 kDa trimeric form of mapmodulin/PHAPI (this study). Li et al. (6, 7) stated that differences in protein phosphatase 2A inhibitor activity in the extracts from control and isopropyl-1-thio-β-D-galactopyranoside-treated cells could not be distinguished prior to chromatography on poly(1-lysine)-agarose. These results imply that I$_1^{PP2A}$ may be active in an aggregated form. We have shown that the native form of PHAPI/mapmodulin is not active as a phosphatase inhibitor. However, it remains entirely plausible that under certain conditions in living cells, the potential of mapmodulin to act as a phosphatase inhibitor is in some way unmasked.

We discovered mapmodulin based on its ability to stimulate the microtubule-dependent and cytoplasmic dynein-dependent localization of Golgi complexes in eukaryotic cells. This protein has a number of interesting biochemical features, including regulation by phosphorylation-induced conformational changes and MAP-binding capacity. A future challenge will be to elucidate further the biological roles of the mapmodulin/PHAPI phosphoprotein in mammalian cells.

REFERENCES

1. Corthesy-Theualaz, I., Pauloin, A., and Pfeffer, S. R. (1992) J. Cell Biol. 118, 1335–1345
2. Ulitzur, N., Humbert, M., and Pfeffer, S. R. (1997)Proc. Natl. Acad. Sci. U. S. A. 94, 5084–5089
3. Vaesen, M., Barnikol-Watanabe, S., Goitz, H., Awni, L. A., Cole, T., Zimmermann, B., Kratzen, H. D., and Hilschmann, N. (1994) Biol. Chem. Hoppe-Seyler 375, 113–126
4. Matsuoka, K., Tsukita, S., Sato, S., Nakayama, H., Ichimura, T., Takahashi, N., Yamakuni, T., Song, S.-Y., and Isobe, T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9670–9674
5. Chen, T.-H., Brody, J. R., Romantsev, F. E., Yu, J.-G., Kayler, A. E., Voneiff, E., Kuhajda, F. P., and Pasternak, G. R. (1996) Mol. Biol. Cell. 7, 2045–2056
6. Li, M., Guo, H., and Damuni, Z. (1995) Biochemistry 34, 1988–1996
7. Li, M., Makkinje, A., and Damuni, Z. (1996) Biochemistry 35, 6998–7002
8. Pierre, P., Scheel, J., Rickard, J. E., and Kreis, T. E. (1992)Cell 70, 887–900
9. Pierre, P., Pepperkok, R., and Kreis, T. E. (1994) J. Cell Sci. 107, 1969–1920
10. Warren, G., Davoust, J., and Cockcroft, A. (1984) EMBO J. 3, 2217–2225
11. Scheel, J., and Kreis, T. E. (1991) J. Biol. Chem. 266, 18141–18148
12. Wang, X. M., Peloquin, J. G., Zhai, Y., Bulinski, J. C., and Borisy, G. G. (1996) J. Cell Biol. 132, 345–357
13. Maccioni, R. B., and Cambiazo, V. (1995) Physiol. Rev. 75, 835–864
14. Fink, T. M., Vaesen, M., Kratzen, H. D., Lichter, P., and Zimmer, M. (1995) Genomics 29, 309–310